文献速递头颈与中枢神经肿瘤

EURECA项目:电化学治疗复发头颈部黏膜肿瘤的前瞻性研究

European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers.
PubMed 文献 · Eur J Cancer · 2017-01-01

EURECA项目是一项前瞻性试验,六家欧洲机构评估电化学治疗复发黏膜头颈部肿瘤的疗效。意向性分析显示客观缓解率56%,其中完全缓解19%、部分缓解37%,治疗耐受性总体良好。

要点

  • 电化学治疗复发黏膜头颈部肿瘤客观缓解率达56%,完全缓解率19%。
  • 3例患者治疗后30、34、84个月仍维持完全缓解。
  • 治疗总体耐受良好,但需关注治疗后黏膜肿胀和疼痛管理。

核心结论

  • 电化学治疗可用于可操作的复发黏膜头颈部肿瘤,客观缓解、生存和毒性特征令人鼓舞。

主要发现

  • 意向性分析显示客观缓解率56%,其中完全缓解8例(19%)、部分缓解16例(37%)、稳定10例(23%)、进展3例(7%)、不可评估6例(14%)。
  • 3例患者(7%)在治疗后30、34和84个月仍维持完全缓解。
  • 治疗过程总体耐受良好,治疗后最初几天观察到黏膜肿胀,疼痛和止痛药使用暂时增加,生活质量评估中注意到疲劳和吞咽困难。

关键数值与推荐

  • 37例可评估肿瘤反应、疼痛评分、副作用和生活质量问卷;6例因失访、疾病进展或评估前死亡不可评估。

临床怎么用

  • 电化学治疗可作为复发黏膜头颈部肿瘤患者的局部治疗选择,需注意治疗后黏膜肿胀并计划疼痛管理。

局限性

  • 6例患者因失访、疾病进展或死亡未能评估,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Electrochemotherapy is an effective local treatment for cutaneous tumours and metastases. In this prospective trial, six European institutions investigated electrochemotherapy in recurrent, mucosal head and neck tumours. PATIENT AND METHODS: Forty-three patients with recurrent mucosal head and neck tumours and no further curative or reasonably effective palliative treatment options were enrolled and treated with electrochemotherapy. Patients were treated in general anaesthesia using intravenous or local injection of bleomycin followed by delivery of electric pulses to the tumour area. Primary end-point was local tumour response. Secondary end-points were safety and toxicity, overall and progression free survival, and quality-of-life. RESULTS: Thirty-seven patients were evaluable for tumour response, pain score, side-effects and quality of life questionnaires. Six patients were not evaluable due to lost follow-up, disease progression or death before evaluation. Intention to treat analysis revealed an objective response of 56% (complete response 8 (19%), partial response 16 (37%), stable disease 10 (23%), progressive disease 3 (7%), and not evaluable 6 (14%)). Three patients (7%) remained in complete response at 30, 34, and 84 months post-treatment. The treatment procedure was generally well tolerated. Swelling of the mucosa was observed in the first days after treatment. Pain and use of pain medication rose temporarily; fatigue and dysphagia were also noted in the quality of life assessment. CONCLUSION: Electrochemotherapy can be applied to mucosal head and neck recurrent tumours accessible to the procedure with promising objective response, survival and toxicity profile. Attention should be paid to post-treatment swelling and planning of pain medication. These favourable results indicate that electrochemotherapy could play a role in patients with recurrent head and neck cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Plaschke CC, Bertino G, McCaul JA, et al. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers. Eur J Cancer. 2017. PMID: 29156298. doi:10.1016/j.ejca.2017.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。